Janux Therapeutics (JANX) Profit After Tax (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Profit After Tax data on file, last reported at -$24.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 3.63% year-over-year to -$24.4 million in Q1 2026; TTM through Mar 2026 was -$116.9 million, a 48.27% decrease from a year earlier, with the FY2025 full-year figure at -$113.6 million, down 64.69% from the prior year.
• Profit After Tax for Q1 2026 stood at -$24.4 million, up from -$34.3 million in the prior quarter.
• Over the last five years, Profit After Tax for JANX reached as high as -$7.1 million in Q2 2024 and fell as low as -$34.3 million in Q4 2025.
• Historically, Profit After Tax has averaged -$19.6 million across 5 years, with a median of -$17.5 million in 2023.
• Across the five-year window, Profit After Tax slumped 487.13% in 2022 and soared 60.45% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$15.3 million in 2022, then climbed by 20.92% to -$12.1 million in 2023, then slumped by 66.83% to -$20.2 million in 2024, then slumped by 69.89% to -$34.3 million in 2025, then rose by 29.07% to -$24.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$24.4 million in Q1 2026, -$34.3 million in Q4 2025, and -$24.3 million in Q3 2025.